4363 related articles for article (PubMed ID: 28838390)
21. Elevated pretreatment neutrophil/white blood cell ratio and monocyte/lymphocyte ratio predict poor survival in patients with curatively resected non-small cell lung cancer: Results from a large cohort.
Yuan C; Li N; Mao X; Liu Z; Ou W; Wang SY
Thorac Cancer; 2017 Jul; 8(4):350-358. PubMed ID: 28544400
[TBL] [Abstract][Full Text] [Related]
22. Are neutrophil/lymphocyte and platelet/lymphocyte rates in patients with non-small cell lung cancer associated with treatment response and prognosis?
Unal D; Eroglu C; Kurtul N; Oguz A; Tasdemir A
Asian Pac J Cancer Prev; 2013; 14(9):5237-42. PubMed ID: 24175807
[TBL] [Abstract][Full Text] [Related]
23. Neutrophil-to-lymphocyte ratio after four weeks of nivolumab administration as a predictive marker in patients with pretreated non-small-cell lung cancer.
Takeda T; Takeuchi M; Saitoh M; Takeda S
Thorac Cancer; 2018 Oct; 9(10):1291-1299. PubMed ID: 30126063
[TBL] [Abstract][Full Text] [Related]
24. Post-treatment changes in hematological parameters predict response to nivolumab monotherapy in non-small cell lung cancer patients.
Khunger M; Patil PD; Khunger A; Li M; Hu B; Rakshit S; Basu A; Pennell N; Stevenson JP; Elson P; Panchabhai TS; Velcheti V
PLoS One; 2018; 13(10):e0197743. PubMed ID: 30359383
[TBL] [Abstract][Full Text] [Related]
25. Neutrophil to Lymphocyte Ratio as a Prognostic Factor in European Patients with Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Treated with Tyrosine Kinase Inhibitors.
Aguiar-Bujanda D; Dueñas-Comino A; Saura-Grau S; Ros-Sanjuan L; Blanco-Sanchez MJ; Hernandez-Sosa M; Mori-De Santiago M; Galvan-Ruiz S; Lorenzo-Barreto JE; Vargas-Prado AM; Bohn-Sarmiento U
Oncol Res Treat; 2018; 41(12):755-761. PubMed ID: 30419558
[TBL] [Abstract][Full Text] [Related]
26. Dynamic evaluation of neutrophil-to-lymphocyte ratio as prognostic factor in stage III non-small cell lung cancer treated with chemoradiotherapy.
Palomar-Abril V; Soria-Comes T; Campos ST; Ureste MM; Bosch VG; Maiques ICM
Clin Transl Oncol; 2020 Dec; 22(12):2333-2340. PubMed ID: 32449125
[TBL] [Abstract][Full Text] [Related]
27. Neutrophil-to-lymphocyte ratio as an early marker of outcomes in patients with advanced non-small-cell lung cancer treated with nivolumab.
Nakaya A; Kurata T; Yoshioka H; Takeyasu Y; Niki M; Kibata K; Satsutani N; Ogata M; Miyara T; Nomura S
Int J Clin Oncol; 2018 Aug; 23(4):634-640. PubMed ID: 29442281
[TBL] [Abstract][Full Text] [Related]
28. Preoperative platelet to lymphocyte and neutrophil to lymphocyte ratios are independent prognostic factors for patients undergoing lung cancer radical surgery: A single institutional cohort study.
Lan H; Zhou L; Chi D; Zhou Q; Tang X; Zhu D; Yue J; Liu B
Oncotarget; 2017 May; 8(21):35301-35310. PubMed ID: 27845912
[TBL] [Abstract][Full Text] [Related]
29. A composite biomarker of neutrophil-lymphocyte ratio and hemoglobin level correlates with clinical response to PD-1 and PD-L1 inhibitors in advanced non-small cell lung cancers.
Ayers KL; Ma M; Debussche G; Corrigan D; McCafferty J; Lee K; Newman S; Zhou X; Hirsch FR; Mack PC; Liu JJ; Schadt EE; Chen R; Li SD
BMC Cancer; 2021 Apr; 21(1):441. PubMed ID: 33882890
[TBL] [Abstract][Full Text] [Related]
30. The relationship between NLR/PLR/LMR levels and survival prognosis in patients with non-small cell lung carcinoma treated with immune checkpoint inhibitors.
Liu N; Mao J; Tao P; Chi H; Jia W; Dong C
Medicine (Baltimore); 2022 Jan; 101(3):e28617. PubMed ID: 35060536
[TBL] [Abstract][Full Text] [Related]
31. Neutrophil-lymphocyte and platelet-lymphocyte ratios as prognostic factors after stereotactic radiation therapy for early-stage non-small-cell lung cancer.
Cannon NA; Meyer J; Iyengar P; Ahn C; Westover KD; Choy H; Timmerman R
J Thorac Oncol; 2015 Feb; 10(2):280-5. PubMed ID: 25299234
[TBL] [Abstract][Full Text] [Related]
32. Impact of neutrophil-lymphocyte and platelet-lymphocyte ratio on antiEGFR and bevacizumab efficacy in metastatic colorectal cancer.
Dogan E; Bozkurt O; Sakalar T; Derin S; Inanc M; Ozkan M
J BUON; 2019; 24(5):1861-1869. PubMed ID: 31786848
[TBL] [Abstract][Full Text] [Related]
33. Prognostic models to predict survival in patients with advanced non-small cell lung cancer treated with first-line chemo- or targeted therapy.
Berardi R; Rinaldi S; Santoni M; Newsom-Davis T; Tiberi M; Morgese F; Caramanti M; Savini A; Ferrini C; Torniai M; Fiordoliva I; Bower M; Cascinu S
Oncotarget; 2016 May; 7(18):26916-24. PubMed ID: 27029035
[TBL] [Abstract][Full Text] [Related]
34. The value of blood biomarkers of progression and prognosis in ALK-positive patients with non-small cell lung cancer treated with crizotinib.
Yang Y; Xu H; Yang G; Yang L; Li J; Wang Y
Asia Pac J Clin Oncol; 2020 Feb; 16(1):63-69. PubMed ID: 31721468
[TBL] [Abstract][Full Text] [Related]
35. Neutrophil to lymphocyte ratio as a potential predictive marker for treatment with pembrolizumab as a second line treatment in patients with non-small cell lung cancer.
Petrova MP; Eneva MI; Arabadjiev JI; Conev NV; Dimitrova EG; Koynov KD; Karanikolova TS; Valev SS; Gencheva RB; Zhbantov GA; Ivanova AI; Sarbianova II; Timcheva CV; Donev IS
Biosci Trends; 2020 Mar; 14(1):48-55. PubMed ID: 32023563
[TBL] [Abstract][Full Text] [Related]
36. Neutrophil-lymphocyte ratio, platelet-lymphocyte ratio, neutrophil-platelet score and prognostic nutritional index: do they have prognostic significance in metastatic pancreas cancer?
Dogan M; Algin E; Guven ZT; Baykara M; Kos TF; Bal O; Zengin N
Curr Med Res Opin; 2018 May; 34(5):857-863. PubMed ID: 29161926
[TBL] [Abstract][Full Text] [Related]
37. Prognostic utility of blood inflammation biomarkers before and after treatment on the survival of patients with locally advanced non-small cell lung cancer undergoing stereotactic body radiotherapy.
Fang F; Jia Z; Xie H; Cao Y; Zhu X; Yang XY; Guo X; Zhang H
Clin Respir J; 2024 May; 18(5):e13749. PubMed ID: 38685745
[TBL] [Abstract][Full Text] [Related]
38. Correlation of Neutrophil to Lymphocyte Ratio and Absolute Neutrophil Count With Outcomes With PD-1 Axis Inhibitors in Patients With Advanced Non-Small-Cell Lung Cancer.
Zer A; Sung MR; Walia P; Khoja L; Maganti M; Labbe C; Shepherd FA; Bradbury PA; Feld R; Liu G; Iazzi M; Zawisza D; Nouriany N; Leighl NB
Clin Lung Cancer; 2018 Sep; 19(5):426-434.e1. PubMed ID: 29803574
[TBL] [Abstract][Full Text] [Related]
39. Platelet-lymphocyte ratio is an independent prognostic factor in patients with ALK-positive non-small-cell lung cancer.
Han Y; Wang J; Hong L; Sun L; Zhuang H; Sun B; Wang H; Zhang X; Ren X
Future Oncol; 2017 Jan; 13(1):51-61. PubMed ID: 27523323
[TBL] [Abstract][Full Text] [Related]
40. Relation of baseline neutrophil-to-lymphocyte ratio to survival and toxicity in head and neck cancer patients treated with (chemo-) radiation.
Bojaxhiu B; Templeton AJ; Elicin O; Shelan M; Zaugg K; Walser M; Giger R; Aebersold DM; Dal Pra A
Radiat Oncol; 2018 Nov; 13(1):216. PubMed ID: 30400969
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
